Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
Edgewise Therapeutics Inc (NASDAQ: EWTX) closed the day trading at $12.68 down -2.08% from the previous closing price of $12.95. In other words, the price has decreased by -$2.08 from its previous closing price. On the day, 0.57 million shares were traded. EWTX stock price reached its highest trading level at $13.1801 during the session, while it also had its lowest trading level at $12.46.
Ratios:
For a better understanding of EWTX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 28.87 and its Current Ratio is at 28.87. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Raymond James on July 30, 2025, initiated with a Strong Buy rating and assigned the stock a target price of $46.
On June 30, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $42.
On April 30, 2025, Guggenheim started tracking the stock assigning a Buy rating and target price of $41.Guggenheim initiated its Buy rating on April 30, 2025, with a $41 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 02 ’25 when Russell Alan J sold 1,551 shares for $16.45 per share. The transaction valued at 25,520 led to the insider holds 18,521 shares of the business.
MOORE JOHN R sold 1,930 shares of EWTX for $31,757 on May 02 ’25. The General Counsel now owns 6,531 shares after completing the transaction at $16.45 per share. On May 02 ’25, another insider, KOCH KEVIN, who serves as the President and CEO of the company, sold 4,276 shares for $16.45 each. As a result, the insider received 70,358 and left with 20,619 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EWTX now has a Market Capitalization of 1335787264 and an Enterprise Value of 746162560.
Stock Price History:
The Beta on a monthly basis for EWTX is 0.27, which has changed by -0.25630498 over the last 52 weeks, in comparison to a change of 0.19554341 over the same period for the S&P500. Over the past 52 weeks, EWTX has reached a high of $38.12, while it has fallen to a 52-week low of $10.60. The 50-Day Moving Average of the stock is -9.78%, while the 200-Day Moving Average is calculated to be -43.13%.
Shares Statistics:
Over the past 3-months, EWTX traded about 829.44K shares per day on average, while over the past 10 days, EWTX traded about 689720 shares per day. A total of 105.34M shares are outstanding, with a floating share count of 77.20M. Insiders hold about 26.72% of the company’s shares, while institutions hold 74.25% stake in the company. Shares short for EWTX as of 1752537600 were 11074084 with a Short Ratio of 13.35, compared to 1749772800 on 12531401. Therefore, it implies a Short% of Shares Outstanding of 11074084 and a Short% of Float of 12.36.
Earnings Estimates
Currently, 11.0 analysts are dedicated to thoroughly evaluating and rating the performance of Edgewise Therapeutics Inc (EWTX) in the stock market.The consensus estimate for the next quarter is -$0.44, with high estimates of -$0.36 and low estimates of -$0.46.
Analysts are recommending an EPS of between -$1.56 and -$1.67 for the fiscal current year, implying an average EPS of -$1.63. EPS for the following year is -$1.97, with 11.0 analysts recommending between -$1.44 and -$2.35.
